Revenue Surged 36%; Profit Collapsed 39%. The Gap Explains Why Guidance Is Gone.
A quarter where the headline numbers diverge wildly from organic profit. Strip out the accounting and the one-off hit, and the story shifts from growth to execution risk — and why management won't commit to the rest of the year.
₹6.8 Cr
-39.3% YoY
₹9.8 Cr
-18% YoY (ex-IndAS adj ~₹1.8–2 Cr)
₹33 Cr
+39% YoY
₹107.2 Cr
+36.1% YoY
On the surface, Royal Orchid's Q1 looks like a growth quarter: revenue up 36%, EBITDA up 39%. But the profit number tells the opposite story. PAT fell 39% YoY to ₹6.8 Cr despite revenue surging and EBITDA expanding. Even adjusting for IndAS accounting (~₹1.8–2 Cr drag), organic PAT is down 18% YoY. The gap between headline growth and profit collapse is where the quarter's truth lives.
Where the profit went
Revenue rose 36% YoY to ₹107 Cr
SupportedDelivered ₹107.2 Cr, +36.1% YoY
EBITDA grew 39% YoY to ~₹33 Cr, margin 30.7%
SupportedOPM 23.7%, EBITDA margin 30.7%; numbers align
Strong top-line momentum; new property ramp explains profit divergence
OverstatedRevenue +36% but PAT -39%. Non-IndAS PAT still down 18% YoY. New 237 rooms contributed only management fees (negligible).
ICONIQA will drive yield improvement and premiumization
ContradictedICONIQA occupancy averaged 70% in Q1 (April 79%, May 60%, June 70%) vs Q4's 80%. Revenue contribution negligible; facing 1,000 new competing keys nearby.
We are at 17–18% ROCE, targeting 20%+ once ICONIQA stabilizes
UnverifiedPAT flat ~₹50 Cr for 3+ years despite 2.5x room growth (4k–5k → 7k+ keys). ROCE figure not independently verified.
The precision that matters: adjusted profit
Peel back the reported number and the picture clarifies. IndAS accounting (~₹1.8–2 Cr non-cash charge related to lease and revenue-share model assets) and a GST rule change (₹2.5 Cr input credit loss) account for ₹4–4.5 Cr of the miss. But even the non-IndAS PAT of ₹9.8 Cr is down 18% YoY versus the implied prior-year adjusted PAT of ~₹12 Cr. Organic profit — the kind a holder can bank on — neither grew nor held flat. It declined. The reason: employee costs jumped to 23% of revenue (from 19–20% historically), ICONIQA is still in gestation, and the new asset-light model (revenue-share, leases) carries higher operating drag than the core portfolio.
Three years back we were at ₹50 Cr PAT, this year also we may end up somewhere there, we've moved from 4,000, 5,000 rooms to 8,000, 10,000 rooms. When does the needle move?
What changed on this call
Guidance withdrawn. Prior call (FY26): 'expect better results after Q1.' This call: no FY27–28 guidance given. War cited, but structural profit headwinds (employee costs, GST, ICONIQA ramp) unresolved.
ICONIQA occupancy miss downgraded. Q4 stated 80%, Q1 actual 70% average (May as low as 60%). Competitive pressure (Fairmont, Hilton, Roswin = 1,000 new keys nearby) underplayed.
Management fee contribution materially lower. All 237 new rooms added in Q1 in managed/franchise model. CFO stated contribution 'very, very negligible' (only fees, not revenue share). Profit uplift deferred.
Asset-light model cost structure clarified. Revenue-share and lease models carry IndAS drag and ongoing interest. Not zero-capex; shifts P&L profile unfavorably vs. core hotels.
Regulatory headwind materialized. GST rule change (rates <₹7,500 now 5% GST without input credit) hit Q1 with ₹2.5 Cr loss. Mitigation unclear.
How the street is reading it
The market's reaction confirmed the miss. On day 1 after the result, the stock fell 1.35%, and the decline held: by day 5 it was off 1.86%, with 89.1% delivery (conviction selling). The stock is now at ₹301.55, down 39% from its all-time high of ₹495 and trading below its 20-day, 50-day, and 200-day moving averages — a clear downtrend. RSI is 40.4 (neutral, not oversold), suggesting the market is repricing rather than panicking.
Ownership tells a steady story: FII holdings rose modestly to 8.57% (+0.03pp), DII remains negligible at 0.91% (+0.04pp), and promoters held flat at 64.06% — no insider capitulation or buying signal. The stock is down 39% from ATH, not from recent highs, implying the drawdown reflects a structural repricing over months, not a single-quarter shock. Institutions are nibbling (FII +0.03pp) but not loading up, consistent with a 'wait and see' posture on execution.
The bull-bear ledger
Bull: Asset-light model and large signed pipeline (50 hotels, 11,000+ rooms over 18–24 months) offer structural revenue upside. Revenue +36% is genuine and driven by ADR strength (JLO portfolio +13.6% YoY to ₹6,233) and occupancy hold (70%), not fantasy.
Bull: EBITDA margin of 30.7% is healthy and expanded 70 bps YoY, signaling operational leverage. Core hotel business (JLO) performing; new brand positioning (Regenta, ICONIQA) is credible.
Bear: PAT flat ~₹50 Cr for 3+ years despite 2.5x room growth is a red flag for capital ROI. This quarter PAT -39% YoY despite revenue +36% suggests asset-light = low-margin.
Bear: ICONIQA underperforming: 70% occupancy vs 80% prior. War impact cited, but 1,000 new competing keys and brand immaturity (7 months old) are real. Revenue contribution negligible; large sunk capex at risk if ramp doesn't inflect.
Bear: Employee cost inflation (19–20% → 23% of revenue) and GST surprise (₹2.5 Cr) represent structural and regulatory headwinds. Management promised stabilization in 1–2 years but offered no concrete action plan.
Bear: Guidance withdrawn. Prior promise ('better results after Q1') broken. Management now cites war scenario and offers no timeline for profit inflection. Credibility grade: C.
Risks, ranked by holder impact
PAT stall despite 2.5x room growth — capital ROI unproven
HighThree years of flat ₹50 Cr PAT while rooms grew from 4k–5k to 7k+ suggests new assets are either capital-intensive, low-margin, or both. This quarter confirms: even ex-IndAS/GST, PAT down 18% YoY. If this persists, asset-light = profit ceiling.
ICONIQA profitability at risk — 70% occupancy, 1,000 new competing keys, large sunk capex
HighICONIQA opened Nov 2025, 7 months old, occupancy already below prior-quarter levels (70% vs 80%) and facing new entrants. If ramp stalls, ₹80–100 Cr capex sits on the balance sheet with limited returns.
Regulatory headwind — GST rule change cost ₹2.5 Cr in Q1; relief timeline unclear
HighOne-off impact in Q1, but if other segments face similar rate regime changes (property tax, labour codes, etc.), drag could recur. Represents ₹10 Cr annual run-rate if unresolved.
Employee cost inflation outpacing revenue — 23% of revenue, no offset plan
MediumNew wage code and increments structural; management promises stabilization in 1–2 years but profit hasn't budged. If cost-cutting doesn't materialize, margins will compress further.
Geopolitical headwind persisting — 50% of Indian inbound via Middle Eastern carriers now zero; duration of conflict unknown
MediumBusiness-hotel segment hit harder in Q1. Domestic leisure offsetting, but ICONIQA and managed portfolio both depend on travel recovery. Risk: ramp delayed 2–3 quarters if conflict extends.
What to watch next
1 · Q2–Q4 organic PAT trend (non-IndAS, ex-GST)
Does PAT inflect or remain flat? Management blamed Q1 on ICONIQA gestation + war + GST + IndAS. If Q2–Q4 shows recovery (even modest), the narrative flips. If profit remains stuck despite EBITDA growth, execution risk is confirmed and guidance withdrawal was justified.
2 · ICONIQA occupancy and ADR pathway into Q2–Q4
War cited as Q1 driver (50% inbound gone, 1,000 new competitor keys). By Q2–Q3, does occupancy recover to 75%+? Does ADR begin stepping up (Year 2 uplift promised)? If not, the ₹85 Cr breakeven target is at risk and the hotel becomes a multi-year drag.
3 · Signed pipeline opening cadence and margin contribution
Management guides 50+ hotels, 11,000+ keys over next 18–24 months. If most are in managed (negligible revenue-share) or asset-light models, profit uplift will be further delayed. Watch: what % of new rooms are JLO (owned/leased, higher margin) vs. managed (low margin)?
The debate
The single number to track
Non-IndAS PAT (adjusted for one-off items). Reported PAT is too noisy (IndAS, GST, depreciation). Non-IndAS PAT of ₹9.8 Cr this quarter (down 18% YoY vs ₹12 Cr prior) is the organic profit. By Q4 FY27, watch if this metric turns positive YoY. If it doesn't, the asset-light thesis is broken. If it does, the rebound has credibility and the stock deserves a re-rate.
Royal Orchid's Q1 is a steady-state quarter masquerading as a growth miss. Revenue growth is real (36%), EBITDA is healthy (30.7% margin), and the signed pipeline is large (11,000+ rooms). But profit — the ultimate measure — fell, and even adjusting for one-offs, organic PAT is down year-on-year. The company missed implicit guidance (profit recovery after Q1 didn't happen), withdrew forward guidance (citing war), and is now relying on ICONIQA to be the lever. ICONIQA is 7 months old and already below occupancy targets, facing new competition and dealing with inbound travel disruption.
Management is not mendacious, but it is cautious — and for good reason. Three years of room growth without profit leverage is a legitimate concern. The path back to credibility is concrete: organic PAT inflection by year-end FY27, ICONIQA occupancy north of 75%, and proof that the signed pipeline lifts margins, not just revenue. For now, it's a Hold. The stock is down 39% from ATH and trades below all key averages; that repricing is fair. The next move depends on execution, not multiple expansion.
Informational and educational content only. Not investment advice.